TY - JOUR T1 - <em>SMAD3</em> Is Upregulated in Human Osteoarthritic Cartilage Independent of the Promoter DNA Methylation JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.150609 SP - jrheum.150609 AU - Erfan Aref-Eshghi AU - Ming Liu AU - Seyd Babak Razavi-Lopez AU - Kensuke Hirasawa AU - Patricia E. Harper AU - Glynn Martin AU - Andrew Furey AU - Roger Green AU - Guang Sun AU - Proton Rahman AU - Guangju Zhai Y1 - 2015/12/15 UR - http://www.jrheum.org/content/early/2015/12/08/jrheum.150609.abstract N2 - Objective To compare SMAD3 gene expression between human osteoarthritic and healthy cartilage and to examine whether expression is regulated by the promoter DNA methylation of the gene. Methods Human cartilage samples were collected from patients undergoing total hip/knee joint replacement surgery due to primary osteoarthritis (OA), and from patients with hip fractures as controls. DNA/RNA was extracted from the cartilage tissues. Real-time quantitative PCR was performed to measure gene expression, and Sequenom EpiTyper was used to assay DNA methylation. Mann-Whitney test was used to compare the methylation and expression levels between OA cases and controls. Spearman rank correlation coefficient was calculated to examine the association between the methylation and gene expression. Results A total of 58 patients with OA (36 women, 22 men; mean age 64 ± 9 yrs) and 55 controls (43 women, 12 men; mean age 79 ± 10 yrs) were studied. SMAD3 expression was on average 83% higher in OA cartilage than in controls (p = 0.0005). No difference was observed for DNA methylation levels in the SMAD3 promoter region between OA cases and controls. No correlation was found between SMAD3 expression and promoter DNA methylation. Conclusion Our study demonstrates that SMAD3 is significantly overexpressed in OA. This overexpression cannot be explained by DNA methylation in the promoter region. The results suggest that the transforming growth factor-β/SMAD3 pathway may be overactivated in OA cartilage and has potential in developing targeted therapies for OA. ER -